Mater Health Services, Raymond Terrace, Brisbane, QLD 4101, Australia.
School of Medicine, University of Queensland, St Lucia, QLD 4072, Australia.
Crit Rev Oncol Hematol. 2016 Jun;102:26-36. doi: 10.1016/j.critrevonc.2016.03.015. Epub 2016 Mar 19.
Mucinous ovarian cancer represents approximately 3% of epithelial ovarian cancers (EOC). Despite this seemingly low prevalence, it remains a diagnostic and therapeutic conundrum that has resulted in numerous attempts to adopt novel strategies in managing this disease. Anecdotally, there has been a prevailing notion that established gold standard systemic regimens should be substituted for those utilised in cancers such as gastrointestinal (GI) malignancies; tumours that share more biological similarities than other EOC subtypes. This review summarises the plethora of small studies which have adopted this philosophy and influenced the design of the multinational GOG142 study, which was ultimately terminated due to poor accrual. To date, there is a paucity of evidence to support delivering 'GI style' chemotherapy for mucinous ovarian cancer over and above carboplatin-paclitaxel doublet therapy. Hence there is an urge to develop studies focused on targeted therapeutic agents driven by refined mutational analysis and conducted within the context of harmonised international collaborations.
黏液性卵巢癌约占上皮性卵巢癌（EOC）的 3%。尽管这种疾病的患病率似乎较低，但它仍然是一个诊断和治疗的难题，导致人们多次尝试采用新的策略来治疗这种疾病。有传闻称，应该用胃肠道（GI）恶性肿瘤等癌症中使用的标准系统方案来替代已确立的标准方案；这些肿瘤与其他 EOC 亚型相比具有更多的生物学相似性。这篇综述总结了许多采用这种理念的小型研究，并影响了多国 GOG142 研究的设计，该研究最终因入组人数不足而终止。迄今为止，几乎没有证据支持在卡铂紫杉醇双药治疗的基础上，用“GI 式”化疗治疗黏液性卵巢癌。因此，迫切需要开展以基于精确基因突变分析的靶向治疗药物为导向的研究，并在协调一致的国际合作框架内进行。
